Trials / Conditions / Recurrent Platinum-Resistant Fallopian Tube Carcinoma

Recurrent Platinum-Resistant Fallopian Tube Carcinoma

6 registered clinical trials studyying Recurrent Platinum-Resistant Fallopian Tube Carcinoma — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without B NCT06393751	National Cancer Institute (NCI)	Phase 1 / Phase 2
Recruiting	MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048	Mayo Clinic	Phase 1
Withdrawn	Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent NCT05295589	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Ca NCT03113487	City of Hope Medical Center	Phase 2
Active Not Recruiting	Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With R NCT02839707	National Cancer Institute (NCI)	Phase 2 / Phase 3